Alvotech reported financial results for the first half of 2025, showing a significant increase in product revenue to $204.7 million compared to $65.9 million in the same period in 2024, driven by the expansion of AVT02 and the launch of AVT04 in multiple countries. Despite a decrease in license and other revenue, the company achieved a net profit of $141.7 million, a substantial turnaround from a net loss in the previous year. Alvotech also announced several strategic initiatives, including a collaboration with Dr. Reddy’s Laboratories for a Keytruda biosimilar and an expanded partnership with Advanz Pharma for additional biosimilar candidates, positioning the company for further growth in the biosimilars market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.